CN102772392A - Arbidol sustained or controlled release capsule and preparation method thereof - Google Patents
Arbidol sustained or controlled release capsule and preparation method thereof Download PDFInfo
- Publication number
- CN102772392A CN102772392A CN2012102985649A CN201210298564A CN102772392A CN 102772392 A CN102772392 A CN 102772392A CN 2012102985649 A CN2012102985649 A CN 2012102985649A CN 201210298564 A CN201210298564 A CN 201210298564A CN 102772392 A CN102772392 A CN 102772392A
- Authority
- CN
- China
- Prior art keywords
- arbidol
- slow
- pill
- release
- release micro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an arbidol sustained or controlled release capsule and a preparation method thereof. The content filled in the sustained or controlled release capsule is arbidol sustained release micro pills with quick release film lagging covers; the arbidol sustained release micro pill consists of the following raw materials in parts by weight: 50 to 400 parts of hydrochloric arbidol, 10 to 500 parts of microcrystalline cellulose, 2 to 100 parts of HPMC K4M and a proper amount of PVP K30 aqueous solution with the concentration of 3 percent; and the quick release film lagging cover consists of the following raw materials in parts by weight: 10 to 100 parts of hydrochloric arbidol, 50 to 100 parts of Eudragit E100, 5 to 50 parts of talcum powder and 500 parts of ethanol with the volumetric concentration of 95 percent. Compared with the prior art, the capsule has a quick response and can sustain a certain blood concentration; the working time of the medicament is prolonged; the medicine taking frequency is obviously reduced; the medicine taking compliance of patients is improved; and the preparation method is simple, easy to control and suitable for industrial production.
Description
Technical field
The present invention relates to medical technical field, be specifically related to a kind of arbidol sustained and controlled release capsule and preparation method thereof.
Background technology
Arbidol (Arbidol) is the efficient medicine of a kind of A of control type and Type B influenza and other acute respiratory virus infection.The mechanism of action is different from antiviral drugs such as ribavirin, amantadine and rimantadine etc. commonly used clinically; It is through inducement interferon, and raise immunity is come resisiting influenza virus; In addition A type and Type B influenza virus all there are antagonism, wider than diamantane (obsolete) amine antiviral spectrum, also have the effect of activated macrophage, treat influenza and other acute respiratory virus infection effectively.Recent research shows that this medicine also has good inhibitory effect to atypia virus under lower safe concentration.Arbidol is by the chemical pharmacy institute research and development of full Russia, and dosage form was a tablet at first in Russia's listing in 1992; The general formulation of domestic research and development has sheet, capsule, dispersible tablet, granule etc., takes every day 3～4 times, and every of specification contains two kinds of 100mg or 200mg.
There are some patents to disclose some formulation and technologies and preparation technique at present about arbidol.
CN 1572298 discloses a kind of compound preparation of antiviral drugs Abiduoer; Influenza compound preparation of the present invention is containing on the basis of arbidol HCl; Also contain ibuprofen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide any one, two or three form; Add the acceptable oral preparation pharmaceutic adjuvant again, process oral dosage form.Various active component concertednesses are good in this compound preparation of medical effect experiment shows, are convenient to the patient and use.
CN 102000030A discloses a kind of this invention of Abiduoer dry suspension and preparation method thereof that is applied in the medical and health industry Abiduoer has been processed after the dry suspension; Effectively cover the bitterness of Abiduoer, improved the compliance that patient takes greatly.
CN 101904826A discloses a kind of arbidol HCl orally disintegrating tablet and preparation method thereof, and this invented technology control is simple, absorbs soon, and bioavailability is high, conveniently takes.
CN 102091048A discloses a kind of method for preparing and method of quality control thereof of arbidol HCl sheet; This technology remedies the deficiency of existing kind; The method for preparing of a kind of broad-spectrum high efficacy, steady quality, technology is simple, with low cost, the patient is easy to accept arbidol HCl sheet is provided, and provide a kind of simple and efficient, quantitatively accurately, the method for quality control of specificity is good, the suitability is strong arbidol HCl sheet.
CN 101653425 discloses a kind of arbidol hydrochloride medicament composition dispersible tablets and preparation method thereof, and its substrate's appearance of the arbidol hydrochloride medicament composition dispersible tablets that this invention provided, hardness and dispersing uniformity are all better.
CN1535680 discloses a kind of new Abiduoer and the molecular clathrate of cyclodextrin or its derivant, and the method for preparing of this clathrate and their application in pharmaceutical preparation.This invention improves its water solublity and stability through preparation Abiduoer clathrate, makes this clathrate can be used as a kind of initiation material or a kind of composition is used to prepare intestinal canal administration or non-intestinal drug delivery agent.
CN 1868470 discloses a kind of Abiduoer granular formulation.This medicine suspendible and good mouthfeel, child and gerontal patient are good to the compliance of this medicine.When arbidol HCl accounts for granule gross weight 5%, can the supplementary product consumption in the former prescription be dropped to 95% by 98%, can reduce the adjuvant inventory, reduce production costs.
Above-mentioned patented technology provides the conventional tablet of arbidol, granule, and suspensoid, dispersible tablet, preparation techniques such as clathrate have improved this bioavailability of medicament to a certain extent, have enlarged the range of application and the practical value of this medicine.But the weak point of these preparation techniques is that this medicine taking dose is big, and medicining times many (taking every day 3～4 times) is for the medication crowd; Improve patient's the compliance of taking; Reduce administration number of times every day, improve the preparation technique of the action effect of medicine simultaneously, will have more captivation undoubtedly.The domestic people of having is developed to the simple slow releasing tablet of taking 2 every day with it at present.
CN 1589790 discloses a kind of slow releasing tablet that relates to the antiviral drugs Abiduoer, and this invention contains the slow releasing tablet of arbidol with hydrophilic gel matrix material or the preparation of waxiness framework material.
But simple sustained-release tablets release is slow, can not discharge active constituents of medicine rapidly, makes maximum plasma concentration lower.In order to improve clinical therapeutic efficacy, we have developed a kind of arbidol sustained and controlled release capsule and preparation method thereof first, not only have slow releasing function; Reduced administration number of times, also had the rapid release effect concurrently, blood drug level is risen rapidly; Thereby bring into play drug effect fast and produce therapeutic effect; Overcome the slow shortcoming of common antiviral slow releasing preparation onset, and method for preparing of the present invention is simple and easy to control, is applicable to suitability for industrialized production.
Summary of the invention
The technical problem that the present invention will solve provides and a kind ofly can satisfy the rapid onset of medicine and can keep arbidol sustained and controlled release capsule of certain blood drug level and preparation method thereof again.
For solving the problems of the technologies described above, arbidol sustained and controlled release capsule of the present invention, the implant in the capsule is covered with the arbidol slow-release micro-pill of rapid release film coating for the surface, and the slow controlled release micro pill of arbidol wherein is made up of the following weight proportion raw material:
Said rapid release film coating is processed by the following weight proportion raw material:
The method for preparing of arbidol sustained and controlled release capsule according to the invention may further comprise the steps:
1) proportioning by the arbidol slow-release micro-pill takes by weighing each raw material, preparation arbidol slow-release micro-pill;
2) put into the coating machine by the arbidol slow-release micro-pill and spray rapid release film coating solution, drying obtains the slow controlled release micro pill of arbidol;
3) encapsulated after the assay was approved.
Above-mentioned method for preparing more specifically may further comprise the steps:
1) take by weighing microcrystalline Cellulose, hypromellose by arbidol slow-release micro-pill prescription and sieve after the arbidol mix homogeneously; Wherein arbidol needs to pulverize earlier; Soft material is processed in the 3%PVP K30 aqueous solution moistening that takes by weighing proportional quantity by prescription again; Put into and extrude finisher,pill and granulate, drying promptly gets the arbidol slow-release micro-pill;
2) the above-mentioned arbidol slow-release micro-pill that makes is put into the coating machine; At the uniform velocity rotate the coating machine, hot-air pre-heating arbidol slow-release micro-pill to 40～60 ℃ sprays rapid release film coating solution with the flow velocity of 1～10g/min to the arbidol micropill; Drying obtains the slow controlled release micro pill of arbidol;
3) encapsulated after the assay was approved.
In the present invention, having no restriction for arbidol, can be any pharmaceutically useful arbidol or its salt.
Among the present invention, also comprise other pharmaceutically acceptable additives in the composition of arbidol slow-release micro-pill and rapid release film coating.Type for affiliated additive does not have concrete restriction; It can be additive conventional in this area; Specifically be to be selected from pharmaceutically acceptable filler, pharmaceutically acceptable disintegrating agent, pharmaceutically acceptable binding agent; Pharmaceutically acceptable wetting agent, one or more in pharmaceutically acceptable film coating material and the pharmaceutically acceptable antiplastering aid.Consumption to other additives has no restriction in the present invention.
Among the present invention, have no restriction for the type of the used filler of arbidol slow-release micro-pill, it is a filler commonly used in this area.Described filler is selected from pregelatinized Starch, microcrystalline Cellulose, lactose, mannitol and their mixture.In the present invention, the amount of filler is not had any restriction, it can be the conventional amount used of this area.In an instance of the present invention, the consumption of described filler is 10～500 weight portions, is preferably 10～200 weight portions, more preferably 20～60 weight portions.
Among the present invention, the controlled slowly releasing adjuncts used for the arbidol slow-release micro-pill has no restriction, and it can be pharmaceutically acceptable conventional controlled slowly releasing adjuncts.In the present invention, the amount of controlled slowly releasing adjuncts is not had any restriction, it can be the conventional amount used of this area.In the present invention, the consumption of described slow-release material is 2～100 weight portions, is preferably 2～50 weight portions, more preferably 5～20 weight portions.
Among the present invention, the binding agent used for the arbidol slow-release micro-pill has no restriction, and it can be pharmaceutically acceptable conventional binding agent.In an instance of the present invention, affiliated binding agent is selected from water or 30 POVIDONE K 30 BP/USP 30 and composition thereof.
Among the present invention, have no restriction for the used coating material of arbidol slow-release micro-pill rapid release film coating part, it can be pharmaceutically acceptable conventional coating material.In the present invention, the amount of coating material is not had any restriction, it can be the conventional amount used of this area.In the present invention, the consumption of described coating material is 5～100 parts, is preferably 5～50 weight portions, more preferably 10～40 weight portions.
Among the present invention, have no restriction for the used antitackiness agent of arbidol slow-release micro-pill rapid release film coating part, it can be pharmaceutically acceptable antitackiness agent.In the present invention, the amount of antitackiness agent is had no restriction, it can be the conventional amount used of this area.In the present invention, the consumption of described antitackiness agent is 5～50 parts, is preferably 5～30 weight portions, more preferably 5～20 weight portions.
Among the present invention, have no restriction for the method for preparing of described arbidol slow-release micro-pill, it can be the method for preparing of the micropill of acceptable routine on the pharmaceutics.In an instance of the present invention; The method for preparing that adopts is: by arbidol slow-release micro-pill prescription take by weighing microcrystalline Cellulose, hypromellose and sieve after the arbidol mix homogeneously; Wherein arbidol needs to pulverize earlier, and soft material is processed in the 3%PVP K30 aqueous solution moistening that takes by weighing proportional quantity by prescription again, puts into to extrude finisher,pill and granulate; Drying promptly gets the arbidol slow-release micro-pill;
Among the present invention, have no restriction for the coating method of described arbidol slow-release micro-pill rapid release film coating, it can be the coating method of acceptable routine on the pharmaceutics.In an instance of the present invention; The method for preparing that adopts is: the above-mentioned arbidol slow-release micro-pill that makes is put into the coating machine; At the uniform velocity rotate the coating machine, hot-air pre-heating arbidol slow-release micro-pill to 40～60 ℃ sprays rapid release film coating solution with the flow velocity of 1～10g/min to the arbidol micropill; Drying obtains arbidol slow-release micro-pill rapid release film coated micropill;
Among the present invention, have no restriction for described capsular type selecting and fill method, it can be capsule type and the model and the fill method of acceptable routine on the pharmaceutics.
Compared with prior art, the invention has the advantages that:
1, the implant micropill nexine of arbidol sustained and controlled release capsule according to the invention is a slow release layer, and skin is a release layer, and release layer is rapid release in the drug release process in vivo; Reach the effect of rapid onset; Nexine is a slow-release micro-pill, after the release layer dissolving, and slowly release; Reach and keep blood drug level, the purpose of lasting onset.Reduce the medication number of times effectively, improved patient's compliance.
2, to have local irritation little for made micropill, and bioavailability is high, and release is stable, and content of dispersion is big, good looking appearance, and good fluidity is loaded the little characteristics of capsules weight difference.
3, the method for preparing of arbidol slow releasing capsule of the present invention is simple, is prone to control, is applicable to suitability for industrialized production.
The specific embodiment
With embodiment the present invention is further specified below, but the present invention is not limited to these embodiment.
Embodiment 1
One, prescription is formed
Two, preparation technology:
(1) arbidol hydrochloride is crushed to 100 orders;
(2) get slow-release micro-pill part recipe quantity arbidol; Microcrystalline Cellulose, HPMC K4M mix homogeneously; Add the 3%PVPK30 aqueous solution and process soft material as wetting agent; Put into and extrude the micropill machine extruding 50 rev/mins and round as a ball 500 rev/mins of system micropills, and under 80 ℃ of conditions dry 2 hours, make the arbidol slow-release micro-pill;
(3) choose above-mentioned 20 purpose arbidol slow-release micro-pill and put into coating pan; Regulating coating machine rotating speed is 150 rev/mins, and the control hot blast temperature is 45 ℃, and the arbidol slow-release micro-pill is preheated to 45 ℃; Spray at 0.04Mpa is depressed; Flow velocity with 6g/min evenly sprays outer rapid release film coating solution to the arbidol slow-release micro-pill, under 30 ℃ of conditions dry 10 hours afterwards, obtains the double-deck micropill of arbidol;
(4) choose the double-deck micropill of 20-50 purpose arbidol, encapsulated after the assay was approved.
Three, implementation result:
According to the dissolution method of 2010 editions two appendix XC first law regulations of Chinese Pharmacopoeia, its 1 hour release degree is 21.3%; The release degree was 33.2% in 2 hours; The release degree was 47.5% in 4 hours; The release degree was 59.4% in 6 hours; The release degree was 72.3% in 8 hours; The release degree was 84.7% in 10 hours; 12 hours release degree is 95.4%.According to the high effective liquid chromatography for measuring of 2010 editions two appendix VD regulations of Chinese Pharmacopoeia, it contains arbidol is 99.3%.
Embodiment 2:
One, prescription is formed
Two, preparation technology:
(1) arbidol hydrochloride is crushed to 100 orders;
(2) get slow-release micro-pill part recipe quantity arbidol; Microcrystalline Cellulose, HPMC K4M mix homogeneously; Add the 3%PVPK30 aqueous solution and process soft material as wetting agent; Put into and extrude the micropill machine extruding 70 rev/mins and round as a ball 650 rev/mins of system micropills, and under 80 ℃ of conditions dry 2 hours, make the arbidol slow-release micro-pill;
(3) choose above-mentioned 20 purpose arbidol slow-release micro-pill and put into coating pan; Regulating coating machine rotating speed is 150 rev/mins, and the control hot blast temperature is 45 ℃, and the arbidol slow-release micro-pill is preheated to 45 ℃; Spray at 0.03Mpa is depressed; Flow velocity with 8g/min evenly sprays outer rapid release film coating solution to the arbidol slow-release micro-pill, under 30 ℃ of conditions dry 10 hours afterwards, obtains the double-deck micropill of arbidol;
(4) choose the double-deck micropill of 20-50 purpose arbidol, encapsulated after the assay was approved.
Three, implementation result:
According to the dissolution method of 2010 editions two appendix XC first law regulations of Chinese Pharmacopoeia, its 1 hour release degree is 33.2%; The release degree was 45.6% in 2 hours; The release degree was 57.1% in 4 hours; The release degree was 68.4% in 6 hours; The release degree was 77.3% in 8 hours; The release degree was 84.7% in 10 hours; 12 hours release degree is 96.8%.According to the high effective liquid chromatography for measuring of 2010 editions two appendix VD regulations of Chinese Pharmacopoeia, it contains arbidol is 101.2%.
Embodiment 3:
One, prescription is formed
Two, preparation technology:
(1) arbidol hydrochloride is crushed to 100 orders;
(2) get slow-release micro-pill part recipe quantity arbidol; Microcrystalline Cellulose, HPMC K4M mix homogeneously; Add the 3%PVPK30 aqueous solution and process soft material as wetting agent; Put into and extrude the micropill machine extruding 70 rev/mins and round as a ball 700 rev/mins of system micropills, and under 80 ℃ of conditions dry 2 hours, make the arbidol slow-release micro-pill;
(3) choose above-mentioned 20 purpose arbidol slow-release micro-pill and put into coating pan; Regulating coating machine rotating speed is 120 rev/mins, and the control hot blast temperature is 45 ℃, and the arbidol slow-release micro-pill is preheated to 45 ℃; Spray at 0.05Mpa is depressed; Flow velocity with 10g/min evenly sprays outer rapid release film coating solution to the arbidol slow-release micro-pill, under 30 ℃ of conditions dry 10 hours afterwards, obtains the double-deck micropill of arbidol;
(4) choose the double-deck micropill of 20-50 purpose arbidol, encapsulated after the assay was approved.
Three, implementation result:
According to the dissolution method of 2010 editions two appendix XC first law regulations of Chinese Pharmacopoeia, its 1 hour release degree is 29.3%; The release degree was 38.2% in 2 hours; The release degree was 50.5% in 4 hours; The release degree was 61.7% in 6 hours; The release degree was 73.7% in 8 hours; The release degree was 84.2% in 10 hours; 12 hours release degree is 93.6%.According to the high effective liquid chromatography for measuring of 2010 editions two appendix VD regulations of Chinese Pharmacopoeia, it contains arbidol is 98.7%.
Claims (5)
1. an arbidol sustained and controlled release capsule is characterized in that the content of filling in the capsule is the surperficial arbidol slow-release micro-pill that is covered with rapid release film coating, and arbidol slow-release micro-pill is wherein processed by the following weight proportion raw material:
Rapid release film coating is made up of the following weight proportion raw material:
。
2. the method for preparing of arbidol sustained and controlled release capsule as claimed in claim 1 may further comprise the steps:
1) proportioning by the arbidol slow-release micro-pill takes by weighing each raw material, preparation arbidol slow-release micro-pill;
2) put into the coating machine by the arbidol slow-release micro-pill and spray rapid release film coating solution, drying obtains the double-deck micropill of arbidol; Wherein,
3) encapsulated after the assay was approved.
3. the composition like right 1 described arbidol slow-release micro-pill and rapid release film coating is characterized in that it comprises the pharmaceutically acceptable additive of 100～5000 weight portions.Described additive is selected from pharmaceutically acceptable filler; Pharmaceutically acceptable disintegrating agent; Pharmaceutically acceptable binding agent; Pharmaceutically acceptable wetting agent, pharmaceutically acceptable slow controlled-release material, one or more in pharmaceutically acceptable film coating material and the pharmaceutically acceptable antitackiness agent.
4. like the method for preparing of right 2 described arbidol slow-release micro-pill; It is characterized in that: by arbidol slow-release micro-pill prescription take by weighing microcrystalline Cellulose, hypromellose and sieve after the arbidol mix homogeneously, wherein arbidol needs to pulverize earlier, soft material is processed in the 3%PVP K30 aqueous solution moistening that takes by weighing proportional quantity by prescription again; Put into and extrude finisher,pill and granulate; Drying promptly gets the arbidol slow-release micro-pill, among the present invention; Method for preparing for described arbidol slow-release micro-pill has no restriction, and it can be the method for preparing of the micropill of acceptable routine on the pharmaceutics.
5. like the method for right 2 described arbidol slow-release micro-pill rapid release film coatings; It is characterized in that: the above-mentioned arbidol slow-release micro-pill that makes is put into the coating machine, at the uniform velocity rotate the coating machine, hot-air pre-heating arbidol slow-release micro-pill to 40～60 ℃; Flow velocity with 1～10g/min sprays rapid release film coating solution to the arbidol micropill; Drying obtains arbidol slow-release micro-pill rapid release film coated micropill, among the present invention; Coating method for described arbidol slow-release micro-pill rapid release film coating has no restriction, and it can be the coating method of acceptable routine on the pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210298564.9A CN102772392B (en) | 2012-08-21 | 2012-08-21 | Arbidol sustained or controlled release capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210298564.9A CN102772392B (en) | 2012-08-21 | 2012-08-21 | Arbidol sustained or controlled release capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102772392A true CN102772392A (en) | 2012-11-14 |
| CN102772392B CN102772392B (en) | 2014-09-24 |
Family
ID=47117656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210298564.9A Active CN102772392B (en) | 2012-08-21 | 2012-08-21 | Arbidol sustained or controlled release capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102772392B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536538A (en) * | 2013-10-23 | 2014-01-29 | 海南康芝药业股份有限公司 | Expansive pellet for effectively masking taste and preparation method thereof |
| CN111821266A (en) * | 2020-07-17 | 2020-10-27 | 迪沙药业集团有限公司 | Taurine sustained-release composition and preparation method thereof |
| CN113304121A (en) * | 2021-06-28 | 2021-08-27 | 石家庄四药有限公司 | Abidol hydrochloride sustained-release capsule and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1742720A (en) * | 2005-09-20 | 2006-03-08 | 江苏吴中苏药医药开发有限责任公司 | Arbidol preparation and preparing method |
| CN101904826A (en) * | 2010-08-12 | 2010-12-08 | 江西中兴汉方药业有限公司 | Arbidol HCl orally disintegrating tablet and preparation method thereof |
| US20120070414A1 (en) * | 2000-10-04 | 2012-03-22 | Paul Stamets | Controlling disease vectors from insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi |
-
2012
- 2012-08-21 CN CN201210298564.9A patent/CN102772392B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120070414A1 (en) * | 2000-10-04 | 2012-03-22 | Paul Stamets | Controlling disease vectors from insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi |
| CN1742720A (en) * | 2005-09-20 | 2006-03-08 | 江苏吴中苏药医药开发有限责任公司 | Arbidol preparation and preparing method |
| CN101904826A (en) * | 2010-08-12 | 2010-12-08 | 江西中兴汉方药业有限公司 | Arbidol HCl orally disintegrating tablet and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536538A (en) * | 2013-10-23 | 2014-01-29 | 海南康芝药业股份有限公司 | Expansive pellet for effectively masking taste and preparation method thereof |
| CN111821266A (en) * | 2020-07-17 | 2020-10-27 | 迪沙药业集团有限公司 | Taurine sustained-release composition and preparation method thereof |
| CN113304121A (en) * | 2021-06-28 | 2021-08-27 | 石家庄四药有限公司 | Abidol hydrochloride sustained-release capsule and preparation method thereof |
| CN113304121B (en) * | 2021-06-28 | 2023-05-09 | 石家庄四药有限公司 | Abidol hydrochloride sustained-release capsule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102772392B (en) | 2014-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU726690B2 (en) | Fluoxetine enteric pellets | |
| WO2011111818A1 (en) | Sustained release type pharmaceutical composition containing mosapride or salt thereof | |
| TW200404009A (en) | High drug load tablet | |
| CN105142618A (en) | Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration | |
| MX2012011022A (en) | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances. | |
| WO2002030400A1 (en) | Solid preparations | |
| CN103402497A (en) | Rapidly dispersing granules, orally disintegrating tablets and methods | |
| JP7156945B2 (en) | Galenic preparations of organic compounds | |
| JP2009537548A (en) | Methods and compositions for the treatment of viral infections | |
| CN107205950B (en) | Method of administering amantadine compositions | |
| CA2650698C (en) | Copolyvidone-containing preparation | |
| WO2023078180A1 (en) | Mini-tablet, and preparation method therefor and formulation thereof | |
| WO2018108157A1 (en) | Rucaparib oral sustained/controlled release pharmaceutical composition and use thereof | |
| CN102258492B (en) | Neostigmine bromide slow release preparation and its preparation method | |
| CN117180218A (en) | Optimized tablet containing high dose mesalamine | |
| ES2566507T3 (en) | Multiparticulate tablets and manufacturing procedure | |
| CN102772392B (en) | Arbidol sustained or controlled release capsule and preparation method thereof | |
| CN103908443A (en) | Propafenone hydrochloride sustained-release capsule and preparation method thereof | |
| CN103251594B (en) | Repaglinide/metformin combo tablet | |
| Gandhi et al. | Recent trends in sustained release drug delivery system | |
| CN103096880A (en) | Drug-containing film-coated particles in which unpleasant taste is masked | |
| Pahade et al. | Formulation and development of a bilayer sustained released tablets of isosorbide mononitrate | |
| CN103282051A (en) | Orally disintegrating tablet | |
| WO2012080703A1 (en) | Pharmaceutical composition comprising imatinib | |
| CN101474166A (en) | Cetirizine and pseudoephedrine sustained-release capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 430074 Hubei city of Wuhan province East Lake high tech Development Zone, Road No. 666 Wuhan humanwell Pharmaceutical Group headquarters Research Institute Applicant after: Ren Fu Pharmaceutical Group stock company Address before: 430074 Hubei city of Wuhan province East Lake high tech Development Zone, Road No. 666 Wuhan humanwell Pharmaceutical Group headquarters Research Institute Applicant before: Wuhan Humanwell Healthcare Group Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HUBEI BIOPHARMACEUTICAL INDUSTRY TECHNOLOGY RESEAR Free format text: FORMER OWNER: HUMANWELL HEALTHCARE GROUP CO., LTD. Effective date: 20150703 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150703 Address after: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666 humanwell Pharmaceutical Group Patentee after: Hubei company limited of Bio-pharmaceutical Industry Institute for Research and Technology Address before: 430074 Hubei city of Wuhan province East Lake high tech Development Zone, Road No. 666 Wuhan humanwell Pharmaceutical Group headquarters Research Institute Patentee before: Ren Fu Pharmaceutical Group stock company |